<DOC>
	<DOC>NCT00617253</DOC>
	<brief_summary>This phase 1/2a trial is conducted in Europe. The first part of the trial is a dose escalation safety trial determining the maximum tolerated dose of rIL-21 when administered in combination with sunitinib. The second part, scheduled to start in September 2008, is a randomised 2-arm trial comparing the anti-tumour effect of rIL-21 plus sunitinib with sunitinib alone.</brief_summary>
	<brief_title>Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologically verified and surgically incurable stage IV Renal Cell Carcinoma ECOG performance status of 0 or 1 (i.e. good performance status) Life expectancy of at least 3 months Prior systemic therapy for metastatic disease Radiotherapy within the last 4 weeks prior to start of treatment Receipt of any investigational drug within 3 months of starting treatment History of any other active malignancy within five years prior to enrolment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>